Advertisement
UK markets closed
  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     
  • FTSE 250

    20,442.35
    -56.37 (-0.27%)
     
  • AIM

    772.57
    +0.19 (+0.02%)
     
  • GBP/EUR

    1.1822
    +0.0000 (+0.00%)
     
  • GBP/USD

    1.2645
    -0.0015 (-0.12%)
     
  • Bitcoin GBP

    50,780.29
    +584.48 (+1.16%)
     
  • CMC Crypto 200

    1,348.51
    -11.81 (-0.87%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • DOW

    39,150.33
    +15.57 (+0.04%)
     
  • CRUDE OIL

    80.59
    -0.70 (-0.86%)
     
  • GOLD FUTURES

    2,334.70
    -34.30 (-1.45%)
     
  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     
  • HANG SENG

    18,028.52
    -306.80 (-1.67%)
     
  • DAX

    18,163.52
    -90.66 (-0.50%)
     
  • CAC 40

    7,628.57
    -42.77 (-0.56%)
     

Olink reports first quarter 2023 financial results

Olink Proteomics AB
Olink Proteomics AB

UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023.

Highlights

  • First quarter 2023 revenue totaled $27.5 million, representing year over year growth of 21% on a reported basis and 25% on a constant currency adjusted like-for-like basis

  • Total Explore customer installations reached 63, with 11 installations during the first quarter

  • Total Signature Q100 placements reached 117, with 26 placements during the first quarter

  • Explore revenue of $16.9 million accounted for 61% of total first quarter revenue, with Explore Kit revenue totaling $9.4 million, or 56% of total Explore revenues

  • First quarter kits revenue and analysis services revenue represented 49% and 38% of total revenue, respectively

  • First quarter 2023 net loss was $(14.0) million, with adjusted EBITDA of $(9.4) million compared to first quarter 2022 net loss of $(12.2) million and adjusted EBITDA of $(9.1) million

  • Exited first quarter 2023 with a cash balance of $173 million

  • Olink expects 2023 full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis; and expects the Company will return to profitability in 2023, as measured by adjusted EBITDA

ADVERTISEMENT

“Olink continues to make significant strides in the next-generation proteomics market by delivering industry-leading revenue growth, financial momentum, and operational execution,” said Jon Heimer, CEO of Olink. “Our culture of innovation and our exceptional ability to deliver enabling solutions to customers has become a driving force in the omics industry, and we look forward to continuing to execute on our strategy.”

First quarter financial results
“During the first quarter we delivered solid performance along key product metrics while maintaining strong financial discipline,” said Oskar Hjelm, CFO of Olink. "In particular, Olink continues to benefit from our strategy of increasing product mix towards kits, helping drive improvement in our corporate margin over the near- to long-term time horizons.”

Total revenue for the first quarter of 2023 was $27.5 million, as compared to $22.7 million for the first quarter of 2022, growing 21% year over year, and driven primarily by strength in kits.

First quarter 2023 kits revenue of $13.5 million represented 49% of total revenue, compared to 18% for the first quarter of 2022; and grew 239% year over year primarily as a result of Explore Kits, with strength from Target as well.

Analysis services revenue for the first quarter of 2023 was $10.4 million, as compared to $16.6 million for the first quarter of 2022.

Other revenue was $3.5 million for the first quarter of 2023, as compared to $2.1 million for the first quarter of 2022. Other revenue growth was driven primarily by Signature Q100 placements.

By geography, revenue during the first quarter of 2023 was $14.7 million in Americas, $8.8 million in EMEA (including Sweden), and $3.9 million in China and RoW (including Japan).

Consolidated reported gross profit was $17.6 million in the first quarter of 2023, as compared to $13.3 million in the first quarter of 2022; while adjusted consolidated gross profit was $18.4 million in the first quarter of 2023, as compared to $14.2 million in the first quarter of 2022.

Reported gross profit margin for kits was 81% for the first quarter of 2023, as compared to 85% for the first quarter of 2022; while adjusted gross profit margin for kits was 83% for the first quarter of 2023, as compared to 89% for the first quarter of 2022.

Reported gross profit margin for analysis services was 56% for the first quarter of 2023, as compared to 54% in the first quarter of 2022; while adjusted gross profit margin for analysis services was 62% as compared to 58% in the first quarter of 2022.

Reported and adjusted gross profit margin for Other was 21% for the first quarter of 2023, as compared to 47% for the first quarter of 2022.

Total operating expenses for the first quarter of 2023 were $34.9 million, as compared to $29.5 million for the first quarter of 2022. The increase was largely due to continued investment into Olink's commercial organization, research and development team expansion, and additional administrative costs.

Net loss was $(14.0) million for the first quarter of 2023 and adjusted EBITDA was $(9.4) million, as compared to a net loss of $(12.2) million and adjusted EBITDA of $(9.1) million for the first quarter of 2022.

Net loss per share for the first quarter of 2023 was $(0.11) based on a weighted average number of outstanding shares of 122,954,966 as compared to a net loss per share of $(0.10) in the first quarter of 2022 based on a weighted average number of outstanding shares of 119,010,097.

2023 guidance
Olink expects 2023 full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis.

The Company also expects revenues in 2023 will continue to progress along a seasonal pattern that is weighted toward the second half of the year, and fourth quarter specifically. In addition, Olink believes with continued growth and scale up, it will return to profitability in 2023, as measured by adjusted EBITDA.

Webcast and conference call details
Company management will host a conference call to discuss financial results at 8:00 am ET. Investors interested in listening to the conference call are required to register online here. A live webcast will be available in the “Events” section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.

Statement regarding use of non-IFRS financial measures
We present certain non-IFRS financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We believe that the use of these non-IFRS measures facilitates investors’ assessment of our operating performance. We caution readers that amounts presented in accordance with our definitions of adjusted EBITDA, adjusted gross profit, adjusted gross profit margin, adjusted gross profit margin by segment, and constant currency revenue growth, may not be the same as similar measures used by other companies. Not all companies and Wall Street analysts calculate the non-IFRS measures we use in the same manner. We compensate for these limitations by reconciling each of these non-IFRS measures to the nearest IFRS performance measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

We are not able to forecast constant currency revenue on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting foreign currency exchange rates and, as a result, are unable to provide a reconciliation to forecasted constant currency revenue.

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

Forward-looking statements
This press release contains express or implied “forward-looking statements,” as defined under the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “seek,” “plan,” “outlook,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “currently,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. You should not place undue reliance on these statements because they involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this press release are based on our management’s beliefs and assumptions and are based upon information currently available to our management as of the date of this press release and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. The forward-looking statements contained in this press release should be read in conjunction with, and are subject to and qualified by, the risks described in the “Risk Factors” section in our Form 20-F for the fiscal year ended December 31, 2022 (Commission file number 001-40277) and elsewhere in the documents we file with the SEC from time to time. Forward-looking statements contained in this press release include, but are not limited to, information about estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and our needs for additional financing; our ability to successfully implement our commercial plans, including the development, launch and scaling of our Explore product line and Olink Signature platform, as well as Olink Flex and Olink Insight; our expectations regarding the rate and degree of market acceptance of our product lines; our need for robust research and development; our competitive position; our ability to develop and commercialize new products; our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; the quarterly progression of our business and major financial metrics, as they relate to the seasonal nature of our customers’ buying patterns.

We undertake no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

 

 

Three months ended March 31

 

 

 

 

 

 

Amounts in thousands of U.S. Dollars unless otherwise stated

Note

2023

 

2022

 

Revenue

4

27,457

 

22,677

 

Cost of goods sold

 

(9,843

)

(9,360

)

Gross profit

 

17,614

 

13,317

 

Selling expenses

 

(11,995

)

(9,465

)

Administrative expenses

 

(16,381

)

(14,399

)

Research and development expenses

 

(6,387

)

(5,985

)

Other operating (expenses)/income

 

(170

)

328

 

Operating loss

 

(17,319

)

(16,204

)

Interest income

 

78

 

1

 

Interest expense

 

(121

)

(131

)

Foreign exchange, net

 

(165

)

1,765

 

Other finance income

 

17

 

 

Loss before tax

 

(17,509

)

(14,569

)

Income tax benefit

5

3,552

 

2,399

 

Net loss for the period (Attributable to shareholders of the Parent)

 

(13,958

)

(12,170

)

Other comprehensive loss:

 

 

 

Items that may be reclassified to profit or loss:

 

 

 

Exchange differences from translation of foreign operations

 

3,102

 

(11,292

)

Other comprehensive income/(loss) for the period, net of tax

 

3,102

 

(11,292

)

Total comprehensive loss for the period, net of tax

 

(10,856

)

(23,462

)

Total comprehensive loss for the period (Attributable to shareholders of the Parent)

 

(10,856

)

(23,462

)

Basic and diluted loss per share

9

(0.11

)

(0.10

)


INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

Amounts in thousands of U.S. Dollars

Note

March 31, 2023 (Unaudited)

 

December 31, 2022 (Audited)

 

ASSETS

 

 

 

Non-current assets

 

 

 

Intangible assets

 

257,170

 

257,480

 

Property, plant and equipment

 

16,649

 

15,056

 

Right-of-use asset

 

9,248

 

9,891

 

Deferred tax assets

5

15,330

 

10,846

 

Other long-term receivables

 

613

 

571

 

Total non-current assets

 

299,010

 

293,844

 

Current assets

 

 

 

Inventories

 

50,908

 

44,246

 

Trade receivables

 

28,290

 

52,743

 

Other receivables

 

894

 

2,562

 

Prepaid expenses and accrued income

 

8,202

 

7,786

 

Cash at bank and in hand

 

172,595

 

75,109

 

Total current assets

 

260,890

 

182,446

 

TOTAL ASSETS

 

559,900

 

476,290

 

EQUITY

 

 

 

Share capital

6

32,221

 

30,988

 

Other contributed capital

6

611,045

 

514,133

 

Reserves/(Deficit)

 

(55,486

)

(58,588

)

Accumulated Deficit

 

(89,805

)

(75,848

)

Total equity attributable to shareholders of the Parent

 

497,974

 

410,685

 

LIABILITIES

 

 

 

Non-current liabilities

 

 

 

Interest-bearing loans and borrowings

7

7,139

 

7,322

 

Deferred tax liabilities

5

21,880

 

22,196

 

Total non-current liabilities

 

29,019

 

29,518

 

Current liabilities

 

 

 

Interest-bearing loans and borrowings

7

1,828

 

2,113

 

Accounts payables

 

6,515

 

6,885

 

Current tax liabilities

 

1,758

 

1,389

 

Other current liabilities

10

22,806

 

25,700

 

Total current liabilities

 

32,906

 

36,086

 

Total liabilities

 

61,926

 

65,605

 

TOTAL EQUITY AND LIABILITIES

 

559,900

 

476,290

 


INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

 

 

Three months ended March 31

Amounts in thousands of U.S. Dollars

Note

2023

 

2022

 

Operating activities

 

 

 

Loss before tax

 

(17,509

)

(14,569

)

Adjustments reconciling loss before tax to operating cash flows:

 

 

 

Depreciation and amortization

 

4,319

 

4,436

 

Net finance expense/(income)

 

190

 

(1,635

)

Loss on sale of assets

 

32

 

464

 

Share-based compensation expense

6

2,105

 

2,179

 

Other

 

25

 

(56

)

Changes in working capital:

 

 

 

(Increase) in inventories

 

(6,299

)

(3,702

)

Decrease in accounts receivable

 

24,708

 

17,662

 

Decrease in other current receivables

 

1,286

 

3,182

 

(Decrease)/Increase in trade payables

 

(414

)

2,098

 

Decrease in other current liabilities

 

(3,053

)

(2,408

)

Interest received

 

78

 

1

 

Interest paid

 

(121

)

(131

)

Other finance income

 

17

 

 

Tax paid

 

(3

)

(985

)

Cash flow from operating activities

 

5,362

 

6,536

 

Investing activities

 

 

 

Purchase of intangible assets

 

(370

)

(327

)

Purchase of property, plant and equipment

 

(2,424

)

(2,090

)

Proceeds from sale of property, plant and equipment

 

5

 

 

Increase in other non-current financial assets

 

(41

)

 

Cash flow used in investing activities

 

(2,830

)

(2,417

)

Financing activities

 

 

 

Proceeds from issue of share capital

6

100,205

 

24

 

Share issue costs

6

(5,026

)

 

Payment of principal portion of lease liability

 

(530

)

(748

)

Cash flow from/(used in) financing activities

 

94,649

 

(724

)

Net cash flow during the period

 

97,180

 

3,395

 

Cash at bank and in hand at the beginning of the period

 

75,109

 

118,096

 

Net foreign exchange difference

 

306

 

(1,280

)

Cash at bank and in hand at the end of the period

 

172,595

 

120,211

 


Reconciliations of adjusted gross profit to gross profit, the most directly comparable IFRS measure, by segment (unaudited):

 

Three months ended March 31

 

Amounts in thousands of U.S. Dollars unless otherwise stated

2023

 

2022

 

Kit

 

 

Revenue

13,534

 

3,994

 

Cost of goods sold

(2,511

)

(603

)

Gross profit

11,023

 

3,391

 

Gross profit margin

81.4

%

84.9

%

Less:

 

 

Depreciation charges

157

 

132

 

Share-based compensation expenses

40

 

36

 

Adjusted Gross Profit

11,220

 

3,559

 

Adjusted Gross Profit %

82.9

%

89.1

%

 

 

 

Service

 

 

Revenue

10,422

 

16,607

 

Cost of goods sold

(4,583

)

(7,663

)

Gross profit

5,839

 

8,944

 

Gross profit margin

56.0

%

53.9

%

Less:

 

 

Depreciation charges

550

 

693

 

Share-based compensation expenses

54

 

30

 

Adjusted Gross Profit

6,443

 

9,667

 

Adjusted Gross Profit %

61.8

%

58.2

%

 

 

 

Corporate / Unallocated

 

 

Revenue

3,501

 

2,076

 

Cost of goods sold

(2,749

)

(1,095

)

Gross profit

752

 

981

 

Gross profit margin

21.5

%

47.3

%

Less:

 

 

Depreciation charges

 

 

Share-based compensation expenses

 

 

Adjusted Gross Profit

752

 

981

 

Adjusted Gross Profit %

21.5

%

47.3

%


Reconciliation of constant currency revenue growth to revenue growth as reported under IFRS, the most directly comparable IFRS measure (unaudited):

We use the non-IFRS measure of constant currency growth, which we define as our total revenue growth from one fiscal year to the next on a constant currency exchange rate basis. We measure our constant currency revenue growth by applying the current fiscal period’s average exchange rate to the prior year fiscal period.

 

Three months ended March 31

Amounts in thousands of U.S. Dollars, unless otherwise stated

2023

 

2022

 

Revenue

27,457

 

22,677

 

Revenue growth (IFRS)

21

%

 

 

Foreign exchange impact

(4

)%

 

 

Constant currency revenue growth

25

%

 

 


Reconciliation of consolidated adjusted gross profit to gross profit, the most directly comparable IFRS measure (unaudited):

 

Three months ended March 31

Amounts in thousands of U.S. Dollars, unless otherwise stated

2023

 

2022

 

Revenue

27,457

 

22,677

 

Cost of goods sold

(9,843

)

(9,360

)

Gross Profit

17,614

 

13,317

 

Gross Profit %

64.2

%

58.7

%

Less:

 

 

Depreciation charges

707

 

824

 

Share-based compensation expenses

94

 

66

 

Adjusted Gross Profit

18,415

 

14,207

 

Adjusted Gross Profit %

67.1

%

62.6

%


Reconciliation of adjusted EBITDA to operating loss, the most directly comparable IFRS measure (unaudited):

 

Three months ended March 31

Amounts in thousands of U.S. Dollars

2023

 

2022

 

Operating income/(loss)

(17,319

)

(16,201

)

Add:

 

 

Amortization

2,733

 

2,974

 

Depreciation

1,586

 

1,462

 

EBITDA

(13,000

)

(11,765

)

Management Adjustments

1,501

 

444

 

Share-based compensation expenses

2,104

 

2,198

 

Adjusted EBITDA

(9,395

)

(9,123

)